Judge rejects Allergan challenge to FCA suit

A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Lawyer opposes Allergan’s bid for interlocutory appeal in FCA suit

18 January 2021 Allergan should not be permitted to immediately appeal against a recent ruling which requires it to face allegations that it monopolised the pricing of dementia drugs, according to a New York-based patent attorney.

Big Pharma

Fed Circuit remands Allergan inventorship dispute

11 November 2020 The US Court of Appeals for the Federal Circuit concluded that a New York judge had rushed to grant summary judgment in an inventorship dispute between Ferring and Allergan.

Big Pharma

FTC demands AbbVie divests Crohn’s treatment in Allergan buyout

7 September 2020 The US Federal Trade Commission has approved a final order regarding charges that biopharmaceutical company AbbVie’s $63 billion acquisition of Allergan would violate US federal antitrust law.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Judge rejects Allergan challenge to FCA suit

More on this story

Editor's picks

Editor's picks

More features